Xtx Topco LTD Erasca, Inc. Transaction History

Xtx Topco LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.79 - $2.63 $35,626 - $52,344	-19,903 Reduced 8.72%	208,424 $491,000
Q1 2024 May 13, 2024	SELL	$1.67 - $2.55 $10,551 - $16,110	-6,318 Reduced 2.69%	228,327 $470,000
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.49 $211,720 - $315,679	126,779 Added 117.53%	234,645 $499,000
Q3 2023 Nov 13, 2023	SELL	$1.97 - $2.91 $13,047 - $19,272	-6,623 Reduced 5.78%	107,866 $212,000
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $153,107 - $196,597	59,575 Added 108.49%	114,489 $315,000
Q1 2023 May 12, 2023	BUY	$2.74 - $4.44 $47,580 - $77,100	17,365 Added 46.25%	54,914 $165,000
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $98,996 - $218,097	25,449 Added 210.32%	37,549 $161,000
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $70,422 - $129,228	12,100 New	12,100 $94,000

141

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $333M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.